Last $7.13 USD
Change Today -0.01 / -0.14%
Volume 400.9K
ARAY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 5:20 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

accuray inc (ARAY) Snapshot

Open
$7.20
Previous Close
$7.14
Day High
$7.24
Day Low
$7.10
52 Week High
02/3/14 - $10.85
52 Week Low
11/1/13 - $6.46
Market Cap
551.2M
Average Volume 10 Days
455.5K
EPS TTM
$-0.47
Shares Outstanding
77.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCURAY INC (ARAY)

accuray inc (ARAY) Related Businessweek News

No Related Businessweek News Found

accuray inc (ARAY) Details

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors in Europe, Japan and rest of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

1,026 Employees
Last Reported Date: 08/29/14
Founded in 1990

accuray inc (ARAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $637.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $293.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $368.1K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $330.6K
Consultant
Total Annual Compensation: $154.7K
Compensation as of Fiscal Year 2014.

accuray inc (ARAY) Key Developments

Accuray Incorporated Signs Three-Year Group Purchasing Agreement with Premier, Inc

Accuray Incorporated has signed a new, exclusive three-year group purchasing agreement with Premier, Inc. Under the new contract, Accuray's precise, leading-edge, clinically proven tumor treatments became available starting on September 1, 2014, to Premier member hospitals and providers. The Accuray CyberKnife M6 Series and TomoTherapy H Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available at present. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

Accuray Incorporated Signs Exclusive Radiation Therapy Solutions Contract with Premier, Inc

Accuray Incorporated announced that it has been awarded a new, exclusive three-year group purchasing agreement with Premier Inc. covering the CyberKnife(R) M6(TM) and TomoTherapy(R) HDA(TM) product portfolios. The Accuray and Premier partnership brings together two companies committed to driving improved patient care through meaningful technical innovation. Under the new contract, Accuray's precise, leading-edge, clinically proven tumor treatments became available starting on September 1, 2014, to Premier member hospitals and providers. Premier unites an alliance of more than 3,000 hospitals and 110,000 other providers, including oncology centers. In addition, the contract provides Accuray with access to key Premier integrated delivery network partners, where Accuray has had limited historical business presence.

Accuray Incorporated Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended June 30, 2014; Provides Earnings Guidance for the Fiscal Year Ending June 30, 2015

Accuray Incorporated announced unaudited consolidated earnings results for fourth quarter and full year ended June 30, 2014. For the quarter, the company reported total net revenue of $102,000,000, loss from operations of $4,667,000, loss before provision for income taxes of $9,336,000, loss from continuing operations of $9,809,000 or $0.13 per basic and diluted share, net loss attributable to stockholders of $9,809,000 or $0.13 per basic and diluted share, adjusted EBITDA of $2,498,000 compared to the total net revenue of $84,900,000, loss from operations of $12,725,000, loss before provision for income taxes of $17,009,000, loss from continuing operations of $18,715,000 or $0.25 per basic and diluted share, net loss attributable to stockholders of $18,715,000 or $0.25 per basic and diluted share, adjusted LBITDA of $5,862,000 for the same quarter a year ago. For the year, the company reported total net revenue of $369,419,000, loss from operations of $18,144,000, loss before provision for income taxes of $32,360,000, loss from continuing operations of $35,448,000 or $0.47 per basic and diluted share, net loss attributable to stockholders of $35,448,000 or $0.47 per basic and diluted share, adjusted EBITDA of $13,276,000 compared to the total net revenue of $315,974,000, loss from operations of $80,655,000, loss before provision for income taxes of $93,788,000, loss from continuing operations of $97,361,000 or $1.33 per basic and diluted share, net loss attributable to stockholders of $103,219,000 or $1.41 per basic and diluted share, adjusted LBITDA of $55,706,000 for the previous year. The company expected fiscal year ending June 30, 2015, revenues to be in the range of $390 million to $410 million. This represents a growth of 6% to 11% over revenues in fiscal 2014. The company expected fiscal 2015 adjusted EBITDA to be in the range of $18 million to $27 million. This represents a growth of 36% to 103% over adjusted EBITDA in fiscal 2014. The company expected fiscal 2015 GAAP net loss to be in the range of $36.700 million to $28.000 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARAY:US $7.13 USD -0.01

ARAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr69.00 SEK +0.20
IsoRay Inc $1.44 USD +0.03
Mitsubishi Heavy Industries Ltd ¥634.00 JPY 0.00
Varian Medical Systems Inc $79.69 USD -1.30
View Industry Companies
 

Industry Analysis

ARAY

Industry Average

Valuation ARAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCURAY INC, please visit www.accuray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.